Our hypothesis in the current study was that targeting TREM2 with an antibody, thereby activating the receptor, would increase TREM2 function leading to immune modulation, clearance of amyloid deposition, and improved cognition without the need to directly target the Aβ peptide itself. Here, TREM2 is linked to amyloidosis.